Opthea to Showcase Revolutionary Retinal Disease Treatments at the ASRS 2023 Annual Meeting!

Opthea Limited (NASDAQ:OPT; ASX:OPT) is excited to announce that their groundbreaking VEGF-C/D “trap” inhibitor, OPT-302, will be featured at the upcoming 2023 American Society of Retina Specialists (ASRS) Annual Meeting in Seattle, Washington.

This impressive organization exhibits the largest membership of retina specialists in the world with over 3,000 members from 63 different countries. As the leading U.S. conference on retinal diseases, this meeting marks an exciting milestone for Opthea Limited and all those impacted by retinal diseases.

At the ASRS conference, Dr. Dante Pieramici MD, Director of the California Retina Research Foundation and Partner at California Retina Consultants, will be presenting exciting new pharmacokinetic and pooled safety data on OPT-302. This fascinating talk is sure to shed light on the latest advances in the realm of retinal treatments and therapies. Don’t miss out on the chance to hear from this premier expert in the field!

Opthea will be a featured guest in a virtual fireside chat discussing market trends and new treatments in wet AMD entitled “Live From ASRS” hosted by Oppenheimer & Co.’s Hartaj Singh, Managing Director and Senior Biotechnology Analyst.

Joining Opthea’s CEO, Dr. Megan Baldwin, on the esteemed panel of expert retina disease specialists are Dr. Charles Wycoff MD, PhD (Director of Research at Retina Consultants of Texas, Chairman of Research, Retina Consultants of America, and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital), and Dr. Dante Pieramici MD. Don’t miss this exciting opportunity to stay on top of cutting-edge treatments and market trends in AMD!

Dr. Baldwin expressed enthusiasm for Opthea’s upcoming data on the pharmacokinetics of OPT-302, which could have a profound impact on vision outcomes for patients with wet AMD—an improvement on the current industry standard of anti-VEGF-A monotherapy. Furthermore, he considers it a great honor that Oppenheimer has chosen to feature the global Phase 3 clinical program of OPT-302 in its ‘Live from ASRS’ KOL forum.

About Opthea Limited

Opthea (ASX:OPT; Nasdaq:OPT) is on a mission to revolutionize the way we treat highly prevalent and progressive retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Through the development of their lead product candidate, OPT-302, Opthea is hoping to achieve greater efficacy and more significant vision gains by inhibiting not only VEGF-A, but also a broader range of VEGF family members. Following a successful completion of pivotal Phase 3 clinical trials, OPT-302 is expected to be used in combination with existing anti-VEGF-A monotherapies.

Leave a Comment